Core Framework & Diagram The Immune Surveillance Theory
7 月 7, 20261 Min Read The Cancer Immunoediting Theory
7 月 7, 2026The cancers you never developed were quietly eliminated by your immune system
——Immune surveillance: a century-long saga of proposal, rejection, and vindication.
I. Theory's birth: Burnet's 'altered self' hypothesis
In 1957, Frank Macfarlane Burnet — the immunology giant who would win the 1960 Nobel Prize for the clonal selection theory — proposed the 'immune surveillance' hypothesis. He noticed a paradox: if gene mutations continuously accumulate in cells, humans should be overwhelmed by cancer at a very young age. Yet the reality is that most people don't develop cancer until old age, and most only once in a lifetime. His explanation: the immune system must be continuously monitoring and eliminating early cancerous cells. Almost simultaneously, Lewis Thomas independently reached similar conclusions — two scientists independently arriving at the same idea typically signals an idea's time has come.
However, this theory faced severe challenges in the 1970s. The nude mouse model (lacking T cells) developed at that time showed no significant increase in spontaneous tumor rates. Many immunologists concluded that immune surveillance theory was wrong, or grossly exaggerated. Later research revealed a fatal flaw in this reasoning: nude mice lacked T cells, but their NK cell function was extraordinarily strong, compensating for T cell absence. So the experiment didn't negate 'immune surveillance' — it only proved 'T cells aren't the only sentinels.' But this correction waited over twenty years.
2. Rebirth: the 2001 precision experiment
In 2001, a landmark experiment published in Nature injected new life into immune surveillance theory. Robert Schreiber's team at Washington University used a more complete immune deficiency model: RAG2 knockout mice. RAG2-/- mice lack both T cells and B cells, with innate immune function also substantially weakened by the absence of lymphocytes. The results were unambiguous: after treatment with a powerful chemical carcinogen, RAG2-/- mice developed tumors at significantly higher frequency than immunologically normal wild-type mice — and tumors appeared earlier and grew larger. Even without any external carcinogen, elderly RAG2-/- mice showed higher spontaneous tumor rates than same-age normal mice.
Even more convincing was the subsequent 'transplant experiment': researchers transplanted tumors grown in RAG2-/- mice into immunologically normal mice, where these tumors were often rejected. But transplanting tumors grown in normal mice into RAG2-/- mice allowed them to grow easily. This means: tumors grown in immune-deficient environments, not having experienced immune selection pressure, retained many 'features the immune system could recognize' — once placed back in an immune environment, they were rapidly eliminated. Tumors grown in normal immune environments had already evolved escape capacity under immune pressure. This was direct experimental evidence for the 'immunoediting' concept.
3. Epidemiological evidence: real-world 'surveillance failure' data
Beyond laboratory data, real-world epidemiological data provides undeniable proof. Large epidemiological studies of organ transplant patients (CTTR research, covering over 200,000 patients across 17+ countries) show that overall cancer incidence risk after organ transplantation is two to four times that of age/sex-matched general populations; non-melanoma skin cancer risk rises sixty-five-fold, Kaposi's sarcoma two hundred-fold, and non-Hodgkin's lymphoma eight-fold.
In HIV/AIDS patients without antiretroviral treatment with severely damaged immune systems (CD4+ T cells below 200/μL), Kaposi's sarcoma risk rises 3,640-fold, non-Hodgkin's lymphoma seventy-seven-fold, and anal cancer approximately forty-five-fold. Patients with congenital immune deficiency syndromes (SCID, ataxia-telangiectasia, etc.) all show significantly higher cancer rates than the general population, especially lymphoma and leukemia. Conversely, prospective studies find that individuals with higher NK cell activity in peripheral blood have lower cancer incidence — these all confirm from a population-level perspective that immune surveillance continuously suppresses cancer.
4. Blind spots of immune surveillance: where failure is most likely
Low immunogenicity tumors (low TMB): pancreatic cancer, prostate cancer, low-grade glioma, etc. have extremely low mutation burdens, producing very few neoantigens — the immune system has insufficient targets to recognize.
Immune-privileged sites: the brain, anterior chamber of the eye, testes, and similar locations are inherently 'dead zones of immune surveillance' — structures like the blood-brain barrier make it difficult for systemic immune cells to enter. Cancers occurring in these sites (like glioblastoma) can quietly grow in relatively immune-undisturbed environments.
Long-term chronic inflammatory environments: this is a paradox — inflammation generally activates the immune system, but long-term chronic inflammation (like hepatitis B-related hepatitis, H. pylori-related gastritis, inflammatory bowel disease) actually 'consumes' immune surveillance efficiency while simultaneously providing a microenvironment that promotes cancer.
Immunosenescence: with advancing age, NK cell numbers decrease and function weakens; CD8+ T cell diversity declines (the TCR repertoire shrinks in older individuals); and the Treg proportion increases relatively. These immunosenescence features directly weaken tumor immune surveillance efficiency — a core immunological mechanism for cancer incidence rising with age. After forty, maintaining overall immune system health is an important foundation for maintaining tumor surveillance efficiency.
5. Clinical application insights from immune surveillance theory
Understanding immune surveillance theory directly points to two different cancer prevention and treatment approaches. Enhancing surveillance efficiency (primarily for cancer prevention): maintaining NK cell and CTL healthy function is the core of primary prevention. Evidence-supported strategies include: regular moderate-to-high intensity aerobic exercise (improves NK cell numbers and cytotoxic activity); adequate sleep (sleep deprivation directly damages NK cell function — a 2019 Nature Communications study showed that four hours of sleep one night causes approximately seventy percent NK cell activity drop the next day); adequate vitamin D; and vaccination against known oncogenic viruses (HPV, hepatitis B).
Blocking escape (primarily for cancer treatment): when cancer has already broken through immune surveillance to enter the 'escape' phase, the treatment goal is no longer to 'enhance' the already-suppressed immune system, but to 'block the tumor's escape mechanisms' — precisely the logic of immune checkpoint inhibitors. PD-1/PD-L1 inhibitors aren't 'enhancing' the immune system; they're 'releasing the brakes the tumor installed,' allowing CTLs already present but suppressed to function again.
Between these — 'intervention during the equilibrium phase' — if equilibrium-phase tumors can be identified through ctDNA liquid biopsy, it may be possible to implement 'preventive immune intervention' before cancer formally escapes. This is a core direction in future cancer early immune intervention research.
6. From tumor antigens to individualized immunotherapy: a technology roadmap
Understanding tumor antigens unlocks understanding of how the most cutting-edge individualized cancer treatments are designed. Here's a simplified technology roadmap: whole exome sequencing (WES) of the patient's tumor tissue and normal tissue to find tumor-specific somatic mutations; bioinformatics algorithms predicting which mutations will produce neoantigen peptides that can bind to that patient's HLA type; synthesizing these neoantigen peptides (as vaccines), or using them to expand and activate the patient's own T cells in vitro (adoptive T cell therapy, ACT); giving the patient individualized vaccines or reinfusing expanded tumor-specific T cells, activating the patient's immune system to directionally attack cancer cells containing these neoantigens; simultaneously using immune checkpoint inhibitors to remove the tumor microenvironment's blockade of activated T cells.
This entire process would have seemed like science fiction ten years ago. Now, with dramatically falling sequencing costs and matured mRNA technology, it has entered clinical trial stages. From sequencing the tumor's mutations, to synthesizing immune weapons exclusive to your tumor, to activating your own immune system for precision attack — this is the closest attempt in medical history to 'medicine tailored specifically for you.'
7. The next step in tumor antigen research: beyond neoantigens
Neoantigen vaccine's rise is exciting, but the frontier of tumor antigen research is extending in deeper directions. Shared neoantigens are a concept receiving increasing attention. While most neoantigens are unique to each patient ('private neoantigens'), certain specific driver mutations (like KRAS G12D, TP53 R175H) appear commonly across many patients, producing identical neoantigens. 'Off-the-shelf' vaccines targeting these 'public neoantigens' don't need individualized customization, can cover patient groups carrying these specific driver mutations, greatly reducing cost and preparation time. mRNA vaccine platform flexibility makes this direction especially attractive.
Non-coding region neoantigens are another emerging direction. Traditional neoantigen prediction focused on exome (protein-coding region) mutations. But recent research found that non-coding region mutations (like introns, long non-coding RNAs) in tumors can also produce neoantigen peptides recognizable by T cells — and in some tumors, the number of non-coding region neoantigens even exceeds coding region neoantigens. Whole genome sequencing (WGS) replacing whole exome sequencing will be the key technical step for next-generation individualized vaccine precision upgrades.
Frequently Asked Questions